Mechanism of action
Donepezil is a piperidine-based, reversible acetylcholinesterase inhibitor with selectivity for central nervous system acetylcholinesterase over butyrylcholinesterase. It binds to the active site of acetylcholinesterase in the synaptic cleft, preventing the hydrolysis of acetylcholine released from presynaptic cholinergic neurons.
By inhibiting the breakdown of acetylcholine, donepezil increases the availability and duration of action of acetylcholine at cholinergic synapses, particularly in the hippocampus and cerebral cortex. These brain regions are critically involved in memory and cognition and show significant cholinergic deficits in Alzheimer's disease due to degeneration of cholinergic neurons in the nucleus basalis of Meynert.
Donepezil does not alter the underlying neurodegenerative process of Alzheimer's disease. It provides symptomatic benefit by compensating for cholinergic deficiency but does not prevent disease progression or neuronal loss. The drug exhibits high selectivity for brain acetylcholinesterase compared to peripheral tissues, though peripheral cholinergic side effects still occur.
- Donepezil is a reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine in the CNS.
- It provides symptomatic improvement in Alzheimer's disease but does not halt neurodegeneration or alter disease progression.
- Most common adverse effects are cholinergic: nausea, diarrhea, and vomiting due to increased GI acetylcholine.
- Bradycardia and syncope can occur due to enhanced vagal tone; use caution in patients with cardiac conduction abnormalities.
- Avoid concurrent anticholinergic drugs, which directly oppose donepezil's mechanism and worsen cognition.
- Donepezil increases gastric acid secretion and risk of peptic ulcers, especially with NSAIDs.
- It prolongs succinylcholine activity during anesthesia due to acetylcholinesterase inhibition.
- Long half-life (70 hours) allows once-daily dosing; steady state reached in approximately 15 days.
Indications
Donepezil is approved for the treatment of dementia of the Alzheimer's type across the full disease spectrum:
- Mild to moderate Alzheimer's disease: First-line symptomatic therapy to improve cognitive function, memory, and activities of daily living
- Severe Alzheimer's disease: Approved for use in advanced stages to maintain function and delay cognitive decline
Off-label uses
- Vascular dementia: Some evidence for cognitive benefit, though not FDA-approved
- Dementia with Lewy bodies: May improve cognition and behavioral symptoms
- Mild cognitive impairment: Studied but not shown to prevent progression to Alzheimer's disease
Donepezil is typically initiated when cognitive impairment begins to affect functional status. It is often continued throughout the disease course as long as the patient tolerates it and derives apparent benefit. The drug provides modest symptomatic improvement in cognitive test scores but does not cure or halt disease progression.
Pharmacokinetics
Absorption: Donepezil is well absorbed after oral administration with approximately 100% bioavailability. Peak plasma concentrations occur within 3 to 4 hours. Food does not significantly affect absorption.
Distribution: The drug is highly protein-bound (approximately 96%) and has a large volume of distribution. It crosses the blood-brain barrier effectively, achieving therapeutic concentrations in the central nervous system.
Metabolism: Donepezil undergoes hepatic metabolism via CYP2D6 and CYP3A4 to multiple metabolites, some of which retain activity. Metabolism is relatively slow, contributing to the long half-life.
Elimination: The elimination half-life is approximately 70 hours, allowing once-daily dosing. Steady-state plasma concentrations are reached in about 15 days. The drug and its metabolites are excreted in urine (approximately 57%) and feces (approximately 15%).
Special populations: Dosage adjustment is not routinely required in renal impairment. Hepatic impairment may increase drug exposure, but specific dosage adjustments are not established. Elderly patients, who are the primary recipients, may have altered pharmacokinetics but are dosed according to tolerability.
Adverse effects
Adverse effects of donepezil are predominantly due to enhanced cholinergic activity. Most are dose-related and occur more frequently during dose titration.
Common cholinergic effects
- Gastrointestinal: Nausea, diarrhea, vomiting, anorexia, and weight loss (most common; occur in 10-20% of patients)
- Neurological: Insomnia, headache, dizziness, fatigue, abnormal dreams
- Musculoskeletal: Muscle cramps
Cardiovascular effects
- Bradycardia: Increased vagal tone can cause sinus bradycardia or heart block, particularly in patients with underlying cardiac conduction abnormalities
- Syncope: May occur due to bradycardia or orthostatic effects
Serious adverse effects
- Peptic ulcer disease and GI bleeding: Cholinergic stimulation increases gastric acid secretion; risk is higher in patients with ulcer history or concurrent NSAID use
- Seizures: Cholinergic drugs may lower seizure threshold
- Bladder complications: Cholinergic effects typically cause urinary urgency and incontinence. However, use with caution in patients with bladder outflow obstruction (such as benign prostatic hyperplasia), as stimulating detrusor contraction against a mechanical obstruction can lead to complications including acute urinary retention or bladder distension
- Bronchoconstriction: May exacerbate asthma or COPD due to increased bronchial secretions and smooth muscle contraction
- QTc prolongation: Rare but documented; caution in patients with cardiac risk factors
Psychiatric effects
- Agitation, aggression, confusion, hallucinations (may represent disease progression rather than drug effect)
Most adverse effects are mild to moderate and often diminish with continued therapy. Gastrointestinal side effects can be minimized by slow dose titration and administration with food.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to donepezil, piperidine derivatives, or any formulation component
Relative contraindications and warnings
- Cardiac conduction disorders: Use with caution in patients with sick sinus syndrome, significant bradycardia, or other supraventricular conduction abnormalities. Donepezil may worsen bradycardia or heart block through vagotonic effects.
- Peptic ulcer disease: Increased risk of gastric acid secretion and GI bleeding. Monitor patients with active or history of peptic ulcers, especially if taking NSAIDs or anticoagulants.
- Seizure disorders: Cholinergic drugs may lower seizure threshold. Use caution in patients with epilepsy.
- Asthma and COPD: Cholinergic bronchial smooth muscle stimulation may precipitate bronchoconstriction. Use cautiously in patients with reactive airway disease.
- Bladder outflow obstruction: Cholinergic stimulation causes detrusor contraction and can lead to complications in patients with bladder outflow obstruction (such as benign prostatic hyperplasia). While cholinergic effects typically promote bladder emptying, contracting the detrusor against a mechanical obstruction can cause acute urinary retention, bladder distension, or other complications.
- Anesthesia: Donepezil may prolong the effects of succinylcholine-type muscle relaxants during anesthesia due to acetylcholinesterase inhibition. Inform anesthesiologists prior to surgery.
Pregnancy and lactation
- Pregnancy category: Not formally assigned under older FDA classification; limited human data. Use only if benefit justifies potential fetal risk.
- Breastfeeding: Unknown if excreted in human milk. Given the patient population (elderly with dementia), this is rarely a clinical concern.
Hepatic and renal impairment
No specific dosage adjustments are recommended, but use caution in severe hepatic impairment.
Drug interactions
Pharmacodynamic interactions
- Anticholinergic drugs: Direct pharmacologic antagonism. Concurrent use of anticholinergics (e.g., oxybutynin, diphenhydramine, tricyclic antidepressants) will reduce the efficacy of donepezil and worsen cognitive function.
- Other cholinesterase inhibitors: Avoid concurrent use (rivastigmine, galantamine) due to additive cholinergic toxicity and lack of additional benefit.
- Beta-blockers and digoxin: Additive bradycardic effects. Monitor heart rate and ECG in patients on these agents.
- Neuromuscular blocking agents: Donepezil prolongs the action of succinylcholine and may antagonize non-depolarizing neuromuscular blockers. Inform anesthesiologists.
- NSAIDs: Additive risk of peptic ulceration and GI bleeding due to increased gastric acid secretion.
Pharmacokinetic interactions
- CYP3A4 and CYP2D6 inducers: Drugs like rifampin, phenytoin, carbamazepine, and phenobarbital may increase donepezil metabolism and reduce plasma levels, potentially decreasing efficacy.
- CYP3A4 and CYP2D6 inhibitors: Ketoconazole, itraconazole, erythromycin, and paroxetine may increase donepezil levels, raising the risk of adverse effects. Dose adjustment is usually not required but monitor for toxicity.
Other considerations
- QTc-prolonging drugs: Additive risk of QTc prolongation and torsades de pointes when combined with other QTc-prolonging agents (e.g., antipsychotics, certain antibiotics).
Overall, drug interactions with donepezil are manageable with awareness and clinical monitoring. Avoid anticholinergic drugs in patients with dementia whenever possible.
Clinical pearls
- Symptomatic benefit only: Donepezil improves cognitive test scores modestly (2-3 points on ADAS-Cog scale) but does not alter the underlying neurodegenerative process or prolong survival. Set realistic expectations with patients and families.
- Titration strategy: Start at lower dose and titrate slowly to minimize gastrointestinal side effects, which are the most common reason for discontinuation. Taking the drug with food may reduce nausea.
- Timing of administration: Traditionally given at bedtime, but if insomnia or vivid dreams occur, switch to morning dosing.
- Duration of therapy: Continue as long as the patient appears to derive benefit and tolerates the medication. Abrupt discontinuation may lead to rapid cognitive decline in some patients.
- Combination with memantine: Often used together in moderate to severe Alzheimer's disease. Memantine (an NMDA receptor antagonist) has a different mechanism and the combination may provide additive benefit.
- Exam context: Donepezil questions often involve recognizing cholinergic side effects (bradycardia, diarrhea) or knowing that acetylcholinesterase inhibitors provide symptomatic treatment without disease modification.
- Peripheral vs. central selectivity: Though donepezil is relatively CNS-selective, peripheral cholinergic effects (GI, cardiac) are common because complete selectivity is not possible.
- Monitoring: No routine laboratory monitoring is required. Monitor for clinical response, tolerability, and heart rate in at-risk patients.
- Discontinuation trials: In advanced dementia, some clinicians attempt discontinuation to assess ongoing benefit, as the drug's efficacy may wane or become unclear in very late stages.
- Differentiating from rivastigmine: Rivastigmine is a pseudo-irreversible inhibitor of both acetylcholinesterase and butyrylcholinesterase with more GI side effects and available as a transdermal patch. Donepezil is more selective and better tolerated.
CHOLINE side effects of cholinesterase inhibitors: Cramping (muscle cramps), Heart block/bradycardia, Overactive GI (nausea, diarrhea), Lower seizure threshold, Increased secretions (bronchial, salivary), Nausea/vomiting, Eyes (miosis, blurred vision).
Practice questions
1. A 72-year-old woman with mild Alzheimer's disease is started on donepezil. Two weeks later, she presents to the clinic complaining of nausea and several episodes of diarrhea each day. Her vital signs are normal, and physical examination is unremarkable. What is the most appropriate next step in management?
2. A 78-year-old man with moderate Alzheimer's disease on donepezil is scheduled for elective inguinal hernia repair under general anesthesia. The anesthesiologist should be informed of the donepezil use because it can:
3. A 68-year-old woman with early Alzheimer's disease is started on donepezil. She has a history of peptic ulcer disease controlled with a proton pump inhibitor and takes daily low-dose aspirin for cardiovascular prevention. Which of the following adverse effects is she at increased risk for?
Frequently asked questions
How does donepezil work?
Donepezil works by reversibly inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine in the brain. This increases the amount and duration of acetylcholine available at synapses, particularly in areas like the hippocampus and cortex that are affected in Alzheimer's disease. By enhancing cholinergic neurotransmission, donepezil temporarily improves memory, cognition, and functional abilities in patients with dementia, though it does not stop the underlying disease process.
What are the side effects of donepezil?
The most common side effects of donepezil are gastrointestinal, including nausea, diarrhea, vomiting, and loss of appetite, which occur due to increased cholinergic activity in the gut. Other frequent effects include insomnia, headache, dizziness, muscle cramps, and fatigue. Cardiovascular side effects such as bradycardia (slow heart rate) and syncope can occur due to increased vagal tone. Serious but less common risks include peptic ulcers, GI bleeding, seizures, urinary urgency or incontinence, and worsening of asthma or COPD. Most side effects are dose-related and improve with slow titration.
Does donepezil cure Alzheimer's disease?
No, donepezil does not cure Alzheimer's disease or stop its progression. It is a symptomatic treatment that temporarily improves cognitive function, memory, and daily living activities by increasing acetylcholine levels in the brain. The underlying neurodegenerative process continues despite treatment. Clinical benefits are modest and typically last for months to a few years before cognitive decline resumes. Donepezil is used to enhance quality of life and maintain function for as long as possible, not to reverse or halt the disease.
Can donepezil cause bradycardia?
Yes, donepezil can cause bradycardia (slow heart rate) due to its cholinergic effects that increase vagal tone on the heart. This can lead to sinus bradycardia, heart block, or syncope, particularly in patients with pre-existing cardiac conduction disorders, those taking beta-blockers, or those on digoxin. Patients at risk should have their heart rate monitored, and donepezil should be used cautiously or avoided in those with sick sinus syndrome or significant bradycardia. The bradycardic effect is a well-recognized adverse reaction in clinical practice and a common exam question.
Donepezil vs rivastigmine — what is the difference?
Both donepezil and rivastigmine are acetylcholinesterase inhibitors used for Alzheimer's disease, but they differ in mechanism and tolerability. Donepezil is a reversible, selective inhibitor of acetylcholinesterase with once-daily dosing and better GI tolerability. Rivastigmine is a pseudo-irreversible inhibitor of both acetylcholinesterase and butyrylcholinesterase, requires twice-daily dosing (or is available as a transdermal patch), and has more gastrointestinal side effects. Rivastigmine is also approved for Parkinson's disease dementia. Efficacy is comparable between the two, so the choice often depends on tolerability and patient preference.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06DA02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.